12-LOX–derived DPAn-6oxylipins, 11-HpDPAn-6and 14-HpDPAn-6, modulate platelet activation through PPAR. Washed human platelets were treated with 10 μM GW6471 (PPARα antagonist) (n = 4) (A), 10 μM GSK3787 (PPARβ antagonist) (n = 4) (B), or 5 μM GW9962 (PPARγ antagonist) (n = 4) (C) for 5 minutes prior to 0.5 to 1 μM incubation with 11-HpDPAn-6 or 14-HpDPAn-6 and platelet aggregation stimulation with EC80 collagen. (D) Similarly, platelets were treated with 1 to 2.5 μM DPAn-6 in the presence of PPAR antagonists prior to collagen-induced aggregation (n = 4). Representative aggregation tracings for 11-HpDPAn-6, 14-HpDPAn-6, and DPAn-6 are shown on the left. (E) A cell-based PPAR transactivation reporter assay was performed in HEK293T cells that had been dose dependently treated with DPAn-6, 11-HpDPAn-6, 14-HpDPAn-6, or PPARα agonist WY 14643 for 8 hours prior to PPARα luciferase assay. Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < .001, ****P < .0001, 1-way statistical tests.